Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05686226 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 22 wordsv8
  2. Study sites: 2 to 3
    • Eligibility criteria shortened, about 4 words
    v7
  3. Primary and study completion dates: Jan 1, 2025 to Jan 1, 2027
    • Collaborators: 1 to 2
    v6
  4. Interventions: E7 TCR-T cells (Biological) to Aldesleukin (Drug), E7 TCR-T cells (Biological)
    • Eligibility criteria expanded, about 506 words
    • Site details revised at 2 of 2 sites
    • Collaborators expanded, about 4 words
    v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 30, 2023 to Mar 7, 2023
    • Site details revised at 2 of 2 sites
    v3
  2. Lead sponsor: Rutgers, The State University of New Jersey to Christian Hinrichsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.
Trial Details
NCT Number NCT05686226
Lead Sponsor Christian Hinrichs
Collaborators: National Cancer Institute (NCI), Iovance Biotherapeutics, Inc.
Conditions
(from sponsor)		 Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer +13 more
Related terms Anus Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Penile Neoplasms, Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov